Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EyePoint Pharmaceuticals (EYPT) just unveiled an update.
EyePoint Pharmaceuticals, Inc. underwent a board reshuffling as Dr. David R. Guyer and Dr. Anthony P. Adamis resigned to take up full-time positions at Merck & Co., with no disagreements with the company. Their departure led to a reduction in board size and the appointment of Fred Hassan, who will also join the Governance and Nominating Committee. Alongside this, new appointments were made to the Compensation and Science Committees. Hassan’s director compensation aligns with the company’s policy, including an option to acquire 60,000 shares of common stock. The company issued a press release regarding these changes on September 4, 2024.
See more data about EYPT stock on TipRanks’ Stock Analysis page.